Company Profile
Aptevo Therapeutics Stock Price, News & Catalysts
- Ticker:
- APVO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.81 USD (-4.42%)
Close
Last updated: August 17, 2026
6.28M USD
Market cap
Why the stock is moving
Following the latest company update, “Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results”, APVO closed down 13.5% at $2.94 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Multispecific Immunotherapy Platforms
Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct.
Mipletamig
Mipletamig is a bispecific antibody candidate designed to redirect T cells toward CD123-expressing leukemia cells. Aptevo is developing the program in frontline acute myeloid leukemia in combination with venetoclax and azacitidine.
RAINIER Frontline AML Study
RAINIER is a Phase 1b/2 study evaluating mipletamig with venetoclax and azacitidine in newly diagnosed AML. The Phase 1b portion is focused on dose optimization and selection of a recommended Phase 2 dose before the program advances into a larger expansion stage.
APVO451
APVO451 is a trispecific solid-tumor candidate directed at nectin-4 and designed to engage immune effector mechanisms. The program is in candidate-selection work ahead of IND-enabling development.
Radiopharmaceutical Collaboration
Aptevo is also working with Niowave under a 50-50 collaboration to develop radiopharmaceutical oncology programs. The partnership combines Aptevo's multispecific binding constructs with Niowave's radioisotope capabilities and may encompass as many as three programs.
Future catalysts
- Completion of RAINIER Phase 1b and selection of the recommended Phase 2 dose for mipletamig by year-end 2026.
- Selection of the APVO451 development candidate by year-end 2026.
- Regulatory interaction regarding the mipletamig Phase 2 program in Q1 2027.
- Initiation of IND-enabling studies for APVO451 in Q1 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aptevo Therapeutics (APVO)?
Aptevo Therapeutics (APVO) most recently closed at 2.81 USD, a -4.42% move versus the previous session.
What is the market cap of Aptevo Therapeutics (APVO)?
Aptevo Therapeutics currently has a market capitalization of 6.28M USD on BioPharmSignal.
What does Aptevo Therapeutics do?
Multispecific Immunotherapy Platforms Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct. Mipletamig Mipletamig is a bispecific antibody...
On which exchange is APVO stock listed?
Aptevo Therapeutics (APVO) is associated with NASDAQ, United States, Biopharma.
What is ADAPTIR-FLEX?
Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct.
Which conditions is Aptevo Therapeutics targeting with ADAPTIR-FLEX?
Aptevo Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Aptevo Therapeutics describe recent progress with ADAPTIR-FLEX?
Completion of RAINIER Phase 1b and selection of the recommended Phase 2 dose for mipletamig by year-end 2026. Selection of the APVO451 development candidate by year-end 2026. Regulatory interaction regarding the mipletamig Phase 2 program in Q1 2027. Initiation of IND-enabling studies for APVO451 in Q1 2027.
What is Multispecific?
Multispecific Immunotherapy Platforms Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer.